ArticleJournal of veterinary pharmacology and therapeutics2026
Should Injectable Meloxicam Be Approved for Use in Cats?
Article in Journal of veterinary pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reply to the Commentary: Should Injectable Meloxicam Be Approved for Use in Cats?Journal of veterinary pharmacology and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Injectable meloxicam remains widely used in feline practice despite its association with acute kidney injury (AKI). Evidence of this association was apparent in the results of a clinical trial submitted to the U.S. Food and Drug Administration as part of a New Animal Drug Application (NADA) Freedom of Information Summary. These data, however, were omitted from the published version of that clinical trial in the Journal of the American Veterinary Medical Association (JAVMA). The study's financial sponsorship by the drug manufacturer raises ethical concerns, especially given meloxicam's ongoing and enthusiastic promotion by veterinary organizations also financially supported by the manufacturer. This viewpoint questions meloxicam's approval process and highlights the potential influence of pharmaceutical industry sponsorship on veterinary prescribing practices and policy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.